1. Home
  2. BBDO vs WAT Comparison

BBDO vs WAT Comparison

Compare BBDO & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Banco Bradesco Sa

BBDO

Banco Bradesco Sa

HOLD

Current Price

$3.13

Market Cap

38.4B

Sector

Finance

ML Signal

HOLD

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$286.12

Market Cap

29.2B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBDO
WAT
Founded
1943
1958
Country
Brazil
United States
Employees
82095
N/A
Industry
Major Banks
Biotechnology: Laboratory Analytical Instruments
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
38.4B
29.2B
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
BBDO
WAT
Price
$3.13
$286.12
Analyst Decision
Strong Buy
Buy
Analyst Count
1
17
Target Price
N/A
$386.38
AVG Volume (30 Days)
82.5K
1.3M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
4.98%
N/A
EPS Growth
N/A
0.47
EPS
N/A
10.76
Revenue
N/A
$3,165,286,000.00
Revenue This Year
$71.06
$104.66
Revenue Next Year
$7.82
$10.53
P/E Ratio
$9.20
$26.34
Revenue Growth
N/A
6.99
52 Week Low
$1.81
$275.05
52 Week High
$3.77
$414.15

Technical Indicators

Market Signals
Indicator
BBDO
WAT
Relative Strength Index (RSI) 34.28 27.08
Support Level $2.89 $281.33
Resistance Level $3.26 $308.14
Average True Range (ATR) 0.14 8.99
MACD -0.06 -1.23
Stochastic Oscillator 0.00 7.60

Price Performance

Historical Comparison
BBDO
WAT

About BBDO Banco Bradesco Sa

Banco Bradesco is Brazil's second-largest private bank, with about 10%-15% of deposits, and the largest insurance provider in Brazil, with roughly 20%-25% market share. The bank is majority controlled by the Bradesco foundation, a private nonprofit institution focused on education. The bank is also a major asset manager with high-single-digit market share. In 2016, Bradesco acquired the Brazilian operations of HSBC.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: